Anti-IL6 Monoclonal antibody, clone C-F9 [FITC]

Aims: Increased expression of inhibitor of apoptosis (IAP) genes has been associated with progressive cancer and chemoresistance. Accordingly, blockade of IAPs by BV6 has resulted in ameliorative outcomes. Interleukin (IL)-6 is another important mediator involved in the growth and survival of tumor cells. Therefore, we hypothesized that simultaneous inhibition of IAPs and IL-6 could be a new promising anti-tumor treatment strategy. Materials and methods: In this study, we generated and characterized hyaluronate-PEG-Chitosan-Lactate (H-PCL) nanoparticles (NPs) to simultaneously deliver IL6-specific siRNA and BV6 to 4T1 (breast cancer) and CT26 (colon cancer) cells, and investigate the anti-tumor properties of this combination therapy both in vitro and in vivo. Key findings: H-PCL NPs exhibited good physicochemical properties leading to efficient transfection of cancer cells and suppression of target molecules. Moreover, combination therapy synergistically increased apoptosis, as well as decreased cell migration, proliferation, colony formation, and angiogenesis in both 4T1 and CT26 cell lines and suppressed cancer progression in tumor-bearing mice that was associated with enhanced survival time. Significance: These findings imply the effectiveness of cancer combination therapy by using H-PCL NPs loaded with anti-IL-6 siRNA and BV6.

Objective Optineurin (OPTN) is an autophagy adaptor/receptor that acts as an intrinsic negative regulator of osteoclast differentiation.RANKLexpressed by rheumatoid arthritis synovial fibroblasts (RASFs) is primarily responsible for the development of bone erosions in patients withRA. The aim of the present study was to explore the role ofOPTNin the pathogenesis of joint destruction inRA. Methods RASFs were left untreated or incubated with tumor necrosis factor (TNF) or interferon-gamma (IFN gamma), and expression ofOPTNbyRASFs was analyzed by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and Western blotting. Expression ofRANKLand osteoprotegerin (OPG) was evaluated in cultures ofOPTN-reducedRASFs with or withoutTNForIFN gamma treatment.OPTN-reducedRASFs were cocultured with monocytes and stained for tartrate-resistant acid phosphatase (TRAP). I kappa B alpha,NF-kappa B1, and RelA protein levels were measured to evaluateNF-kappa B signaling. Expression of messengerRNA(mRNA) for matrix metalloproteinase 3 (MMP3), interleukin-6 (IL6),GATAbinding protein 3 (GATA3), carbohydrate sulfotransferase 15 (CHST15), hyaluronan synthase 1 (HAS1), andGATA1was analyzed byRT-qPCR. Results InRASFs incubated withTNForIFN gamma,OPTNexpression was up-regulated andRANKLexpression was increased, and these effects were further pronounced inOPTN-reducedRASFs (allP< 0.05 versus controls).OPG mRNAlevels remained unchanged. Monocytes cocultured withOPTN-reducedRASFs differentiated to a greater extent intoTRAP+ multinucleated cells compared to monocytes cocultured with controlRASFs (P< 0.05). I kappa B alpha degradation and nuclearNF-kappa B1 expression followingTNFtreatment were both prolonged inOPTN-reducedRASFs (eachP< 0.05 versus controls).MMP3mRNAlevels were up-regulated, whileGATA3,CHST15, andHAS1mRNAlevels were down-regulated inOPTN-reducedRASFs (eachP< 0.05 versus controls). Conclusion OPTNplays a protective role inRAwhen it is up-regulated inRASFs in the presence of proinflammatory cytokines. Absence ofOPTNmight worsenRAby generating a joint-destructive state, as indicated by evidence of increasedRANKLexpression onRASFs and subsequent osteoclast differentiation.